Literature DB >> 10519999

Results at a single centre of immunosuppression with cyclosporine A in 66 children with aplastic anaemia.

A Maschan1, N Bogatcheva, O Kryjanovskii, M Shneider, D Litvinov, T Mitiushkina, A Timakov, M Timakova, E Samotchatova, A Rumiantsev.   

Abstract

A retrospective analysis of cyclosporine A (CsA) monotherapy administered to 66 children with aplastic anaemia (AA) at a single centre was carried out. The study was conducted on 66 children (F34/M32) with a median age of 10.5 years. 30 children (45%) achieved complete or partial remission within a median of 8 weeks. The response rate was 3/19 (16%) in cases of very severe aplastic anaemia (vSAA), 16/34 (47%) in severe aplastic anaemia (SAA) and 11/13 (85%) in nonSAA. 10 remitters (33%) relapsed after CsA cessation or dose tapering and six of those responded again on CsA alone. The only variable predictive for response was granulocyte count before treatment. The actuarial probability of survival was 51% at 4 years (85% in moderate AA, 50% in SAA and 32% in vSAA). The optimal dosage of CsA has yet to be established.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10519999     DOI: 10.1046/j.1365-2141.1999.01650.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Population pharmacokinetics of ciclosporin in Chinese children with aplastic anemia: effects of weight, renal function and stanozolol administration.

Authors:  Shao-qing Ni; Wei Zhao; Jue Wang; Su Zeng; Shu-qing Chen; Evelyne Jacqz-Aigrain; Zheng-yan Zhao
Journal:  Acta Pharmacol Sin       Date:  2013-04-29       Impact factor: 6.150

2.  Outcome of a novel immunosuppressive strategy of cyclosporine, levamisole and danazol for severe aplastic anemia.

Authors:  Min Wang; Xingxin Li; Jun Shi; Yingqi Shao; Meili Ge; Jinbo Huang; Zhendong Huang; Jing Zhang; Neng Nie; Yizhou Zheng
Journal:  Int J Hematol       Date:  2015-06-14       Impact factor: 2.490

Review 3.  Immunosuppressive treatment of acquired aplastic anemia and immune-mediated bone marrow failure syndromes.

Authors:  Neal S Young
Journal:  Int J Hematol       Date:  2002-02       Impact factor: 2.490

4.  Study of Aplastic Anaemia with Cyclosporine in Resource Poor Setting.

Authors:  Mallikarjuna Shetty; Anukonda Moti Venkata Raja Narendra; Krishna Prasad Adiraju; Nageshwar Rao Modugu
Journal:  J Clin Diagn Res       Date:  2016-06-01

Review 5.  Special issues related to the diagnosis and management of acquired aplastic anemia in countries with restricted resources, a report on behalf of the Eastern Mediterranean blood and marrow transplantation (EMBMT) group and severe aplastic anemia working party of the European Society for blood and marrow transplantation (SAAWP of EBMT).

Authors:  Raheel Iftikhar; Parvez Ahmad; Regis de Latour; Carlo Dufour; Antonio Risitano; Naeem Chaudhri; Ali Bazarbachi; Josu De La Fuente; Britta Höchsmann; Syed Osman Ahmed; Usama Gergis; Alaa Elhaddad; Constantijn Halkes; Bassim Albeirouti; Sultan Alotaibi; Austin Kulasekararaj; Hazzaa Alzahrani; Tarek Ben Othman; Simone Cesaro; Ali Alahmari; Rawad Rihani; Salem Alshemmari; Amir Ali Hamidieh; Mohamed-Amine Bekadja; Jakob Passweg; Murtadha Al-Khabori; Walid Rasheed; Andrea Bacigalupo; Qamar-Un-Nisa Chaudhry; Per Ljungman; Judith Marsh; Riad El Fakih; Mahmoud Aljurf
Journal:  Bone Marrow Transplant       Date:  2021-05-19       Impact factor: 5.483

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.